2026 Vivli AMR Surveillance Data Challenge Judges Panel

Henry Skinner, PhD, MS Bioethics, is Chief Executive Officer of the AMR Action Fund. He has spent his career addressing the scientific and economic barriers to antimicrobial drug development. His cross‑disciplinary expertise has been central to shaping AMR Action Fund’s investment strategy and policy priorities, with an emphasis on issues pertaining to R&D, innovative financing, and equitable access. Prior to joining the AMR Action Fund, Dr. Skinner held leadership roles across the pharmaceutical, biotechnology, and venture capital sectors, including at Tekla Capital Management and the Novartis Venture Fund. He completed postdoctoral training in the Department of Molecular and Human Genetics at Baylor College of Medicine and holds a PhD in Microbiology and an MS in Biochemistry from the University of Illinois, an MS in Bioethics from Harvard Medical School, an MJur in Health Law, Policy, and Management from Texas A&M University, and MS and BS degrees from Worcester Polytechnic Institute.